Is Foxglove Effective in Heart Failure?. Issue 4 (7th July 2015)

• Record Type: Journal Article
• Authors: Chaggar, Parminder S; Shaw, Steven M; Williams, Simon G
• Is Part Of: Cardiovascular therapeutics. Volume 33:Issue 4(2015:Aug.)
• Page Start: 236
• Page End: 241
• Publication Date: 2015-07-07
• Subjects: Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1111/1755-5922.12130
• Languages: English
• ISSNs: 1755-5914

Abstract

<abstract abstract-type="main" id="cdr12130-abs-0001"> <title>Summary</title> <sec id="cdr12130-sec-0001" sec-type="section"> <title>Background</title> <p>Digoxin is the oldest known treatment for heart failure (HF) and has been demonstrated to reduce admissions for worsening heart failure in a large randomized trial recruiting patients in sinus rhythm with heart failure and ejection fraction <45%. This study forms the basis for current international guidelines recommending that digoxin should be considered in patients with symptomatic HF despite optimal doses of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, <italic>β</italic>‐blockers, and mineralocorticoid receptor antagonists in addition to device therapy, if indicated. However, digoxin predates mortality reducing HF therapies, and this article reviews the historical and recent data.</p> </sec> <sec id="cdr12130-sec-0002" sec-type="section"> <title>Methods</title> <p>Multiple PubMed searches were performed including, but not limited to, the search terms "digoxin, " "heart failure, " "efficacy, " "treatment, " "side‐effects, " "morbidity, " "mortality, " and "arrythmia." Articles were excluded if not relevant, not in English or without abstract. Reference lists of relevant articles were manually searched for further references. Due to the large number of articles retrieved, a selection was reviewed based on the authors' best judgement.</p> </sec> <sec id="cdr12130-sec-0003" sec-type="section"> <title>Results</title> <p>Three randomized controlled trials and three large contemporary observational reports of digoxin therapy in heart failure and sinus rhythm were retrieved. Other studies were noted that included patients with heart failure and atrial fibrillation, which were also reviewed.</p> </sec> <sec id="cdr12130-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Definitive randomized evidence of digoxin efficacy as add‐on therapy in HF is lacking because most landmark trials of modern HF disease modifying agents postdate the randomized studies of digoxin. Furthermore, questions remain regarding the optimum dose of digoxin and there are signals that digoxin may be harmful in some patients with HF. All contemporary data for digoxin in HF are derived from observational studies and the findings are conflicting. Despite two centuries of experience using cardiac glycosides to treat HF, fundamental questions regarding the efficacy and safety of digoxin in HF remain unanswered.</p> </sec> </abstract>